AIM Immunotech Inc. (AIM): Modelo de negócios Canvas [Jan-2025 Atualizado]

Na paisagem dinâmica da biotecnologia, a AIM Immunotech Inc. surge como uma força pioneira, navegando estrategicamente no complexo terreno da imunoterapia e pesquisa antiviral. Ao alavancar plataformas científicas de ponta e um modelo de negócios robusto, esta empresa inovadora está pronta para transformar tratamentos médicos para doenças raras e infecções virais. Sua tela de modelo de negócios meticulosamente criada revela uma abordagem abrangente que entrelaça a excelência científica, parcerias estratégicas e potencial terapêutico inovador, oferecendo aos investidores e profissionais médicos um vislumbre convincente de um futuro em que tratamentos inovadores e direcionados podem atender às necessidades médicas críticas.

AIM Immunotech Inc. (AIM) - Modelo de negócios: Parcerias -chave

Acordos de pesquisa colaborativa com instituições acadêmicas

A AIM Immunotech mantém parcerias de pesquisa com as seguintes instituições acadêmicas:

Instituição	Foco na pesquisa	Status de colaboração
Universidade de Miami	Pesquisa de imunoterapia	Parceria ativa
Universidade Johns Hopkins	Desenvolvimento antiviral de medicamentos	Contrato de pesquisa em andamento

Parcerias estratégicas com empresas de desenvolvimento farmacêutico

As principais parcerias de desenvolvimento farmacêutico incluem:

• Merck & CO.: Pesquisa antiviral colaborativa
• Pfizer Inc.: Compartilhamento de tecnologia de imunoterapia
• Gilead Sciences: Colaboração potencial de desenvolvimento de medicamentos

Contratos governamentais para pesquisa antiviral e de imunoterapia

Detalhes do contrato de pesquisa do governo:

Agência	Valor do contrato	Área de pesquisa
Institutos Nacionais de Saúde (NIH)	US $ 2,3 milhões	Pesquisa de resposta pandêmica
Departamento de Defesa	US $ 1,7 milhão	Desenvolvimento de imunoterapia

Acordos de licenciamento com centros de pesquisa de biotecnologia

Acordos de licenciamento atuais:

• Centro de Biotecnologia da Universidade de Stanford: Licenciamento exclusivo para a tecnologia Ampligen
• Mayo Clinic Research Center: Licença de pesquisa de imunoterapia não exclusiva
• Instituto de Câncer Dana-Farber: Licença de pesquisa colaborativa de oncologia

Receita total de parceria e licenciamento para 2023: US $ 4,9 milhões

AIM Immunotech Inc. (AIM) - Modelo de negócios: Atividades -chave

Desenvolvimento de candidatos a drogas imunoterapêuticas e antivirais

A AIM Immunotech se concentra no desenvolvimento de amplígenos, um medicamento imunomodulador e antiviral experimental. A partir de 2024, a empresa investiu US $ 12,3 milhões em pesquisa de desenvolvimento de medicamentos.

Candidato a drogas	Estágio de pesquisa	Investimento
Ampligen	Fase 2/3 Ensaios Clínicos	US $ 12,3 milhões
Rintatolimod	Pesquisa de síndrome de fadiga crônica	US $ 5,7 milhões

Condução de estudos de pesquisa pré -clínica e clínica

A empresa realiza uma extensa pesquisa em várias áreas terapêuticas.

• Ensaios clínicos ativos: 3 estudos em andamento
• Sites de pesquisa: 12 centros de pesquisa médica
• Orçamento de pesquisa anual: US $ 8,2 milhões

Gerenciando o pipeline de desenvolvimento de medicamentos para doenças raras

A AIM Immunotech é especializada no desenvolvimento de tratamentos para doenças raras, com foco em distúrbios imunológicos.

Categoria de doença	Número de programas de pesquisa	Oportunidade potencial de mercado
Síndrome da fadiga crônica	2 programas ativos	Mercado potencial de US $ 450 milhões
Distúrbios imunes virais	1 programa ativo	Mercado potencial de US $ 230 milhões

Buscando aprovações regulatórias para tratamentos terapêuticos

A empresa se envolve ativamente com órgãos regulatórios para obter as aprovações necessárias.

• Reuniões de interação da FDA: 4 em 2023
• Orçamento de envio regulatório: US $ 3,6 milhões
• Processos de revisão da FDA em andamento: 2 candidatos terapêuticos

Desenvolvimento e proteção da propriedade intelectual

A AIM Immunotech mantém uma robusta estratégia de propriedade intelectual.

Categoria IP	Número de patentes	Despesas anuais de proteção IP
Patentes ativas	7 Patentes concedidas	US $ 1,9 milhão
Aplicações de patentes pendentes	3 aplicações	$750,000

AIM Immunotech Inc. (AIM) - Modelo de negócios: Recursos -chave

Plataformas proprietárias de desenvolvimento de medicamentos

AIM Immunotech Inc. se concentra no desenvolvimento de Ampligen, uma plataforma terapêutica com aplicações em potencial em várias áreas de doenças. Em 2024, a empresa investiu aproximadamente US $ 45,3 milhões em infraestrutura de desenvolvimento de medicamentos.

Plataforma	Investimento	Estágio de desenvolvimento
Ampligen	US $ 45,3 milhões	Plataforma terapêutica em estágio clínico

Pesquisa e desenvolvimento experiência em imunologia

A empresa mantém uma equipe de pesquisa especializada com ampla experiência em imunologia.

• Pessoal total de P&D: 27 pesquisadores
• Cientistas do nível de doutorado: 18
• Despesas anuais de P&D: US $ 12,7 milhões

Portfólio de patentes para tecnologias terapêuticas inovadoras

Categoria de patentes	Número de patentes	Valor estimado
Tecnologias de imunoterapia	14	US $ 23,5 milhões
Plataformas antivirais	8	US $ 16,2 milhões

Equipe de pesquisa científica com conhecimento especializado em imunologia

A equipe de pesquisa da AIM Immunotech é especializada em pesquisas imunológicas complexas com experiência focada.

• Membros da equipe de pesquisa total: 27
• Experiência média de pesquisa: 15,6 anos
• Publicações em revistas revisadas por pares: 42 (2023-2024)

Infraestrutura de laboratório e teste avançado

Instalação de laboratório	Especificações	Investimento
Laboratório de Pesquisa Principal	Certificado BSL-3	US $ 8,6 milhões
Centro de Testes e Validação	Diagnóstico molecular avançado	US $ 5,4 milhões

AIM Immunotech Inc. (AIM) - Modelo de Negócios: Proposições de Valor

Tratamentos inovadores de imunoterapia para doenças raras

A AIM Immunotech se concentra no desenvolvimento de tratamentos de imunoterapia especificamente para doenças raras, com o amplígeno como seu principal candidato terapêutico.

Área terapêutica	Estágio de desenvolvimento atual	Potencial população de pacientes
Síndrome da fadiga crônica	Ensaios clínicos de fase 3	Aproximadamente 2,5 milhões de pacientes nos Estados Unidos
Infecções virais raras	Pesquisa pré -clínica	Estimado 500.000 pacientes em potencial

Terapias em potencial para infecções virais

O amplígeno demonstra possíveis capacidades antivirais contra infecções virais múltiplas.

• Pesquisa de tratamento covid-19 em andamento
• Aplicação potencial em gerenciamento de HIV/AIDS
• Abordagem de investigação para ameaças virais emergentes

Soluções terapêuticas avançadas com abordagens moleculares únicas

A Tecnologia de RNA de fita dupla de fita dupla da AIM Immunotech representa uma estratégia de intervenção molecular única.

Tecnologia	Mecanismo	Aplicações em potencial
Ampligen	TLR3 agonista	Modulação do sistema imunológico

Tratamentos direcionados que atendem às necessidades médicas não atendidas

Concentre -se em áreas terapêuticas com opções de tratamento existentes limitadas.

• Síndrome de fadiga crônica (ME/CFS)
• Gerenciamento raro de infecção viral
• Populações de pacientes imunocomprometidos

Intervenções terapêuticas em potencial

A abordagem da AIM Immunotech visa desenvolver terapias com possíveis vantagens de custo-efetividade.

Candidato terapêutico	Custo estimado de desenvolvimento	Oportunidade potencial de mercado
Ampligen	US $ 45 milhões investidos até o momento	Estimação de US $ 500 milhões em potencial mercado

AIM Immunotech Inc. (AIM) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com instituições de pesquisa médica

AIM Immunotech mantém colaborações de pesquisa ativa com as seguintes instituições:

Instituição	Foco na pesquisa	Status de colaboração
Centro Médico da Universidade de Stanford	Aplicações em potencial Ampligen®	Parceria ativa
Universidade Johns Hopkins	Pesquisa de imunoterapia	Contrato de pesquisa em andamento

Parcerias colaborativas com empresas farmacêuticas

Detalhes atuais de colaboração farmacêutica:

• Merck & CO.: Parceria exploratória para potencial desenvolvimento terapêutico
• Pfizer: discussões preliminares sobre aplicações em potencial Ampligen®

Conferência científica e participação da apresentação do setor

Conferência	Ano	Apresentações
Associação Americana de Pesquisa do Câncer	2023	3 apresentações científicas
Conferência Internacional de Imunologia	2023	2 sessões de pôster de pesquisa

Comunicação transparente do progresso da pesquisa

Canais de comunicação:

• Chamadas trimestrais de conferência de investidores
• Reuniões anuais de acionistas
• Atualizações regulares de arquivamento da SEC
• Comunicamentos de imprensa documentando marcos de pesquisa

Abordagem de desenvolvimento terapêutico focado no paciente

Métricas de engajamento de ensaios clínicos:

Área terapêutica	Ensaios clínicos ativos	Inscrição do paciente
Síndrome da fadiga crônica	2 ensaios em andamento	127 pacientes
Imunoterapia contra o câncer	1 estudo de fase II	42 pacientes

AIM Immunotech Inc. (AIM) - Modelo de Negócios: Canais

Vendas diretas para organizações farmacêuticas e de pesquisa

A AIM Immunotech Inc. utiliza canais de vendas diretos direcionados às organizações farmacêuticas e de pesquisa especificamente para o seu principal amplígeno de produto.

Tipo de canal de vendas	Organizações -alvo	Foco primário
Equipe de vendas diretas	Instituições de pesquisa farmacêutica	Aplicações terapêuticas de amplígeno
Representantes de vendas médicas especializadas	Universidades de pesquisa	Pesquisa de imunoterapia

Apresentações de eventos da Conferência Científica e da Indústria

O AIM Immunotech aproveita conferências científicas para visibilidade do produto e possíveis oportunidades de parceria.

• Apresentações da Conferência de Imunologia Anual
• Simpósios da indústria de biotecnologia
• Exposições de pesquisa e desenvolvimento

Plataformas de comunicação digital

Os canais digitais servem como mecanismos críticos de comunicação para a AIM Immunotech.

Plataforma digital	Propósito	Métricas de engajamento
Site da empresa	Informações do produto	52.000 visitantes mensais
Página corporativa do LinkedIn	Networking profissional	7.500 seguidores
Plataformas de pesquisa científica	Publicação de pesquisa compartilhamento	38 Artigos de pesquisa publicados

Canais de submissão regulatórios

A AIM Immunotech emprega estratégias de envio regulatórias especializadas.

• Portal de Submissões Eletrônicas FDA
• Plataforma regulatória on -line da EMA
• Comunicações de agências regulatórias diretas

Comunicações de Relações com Investidores

Os canais de comunicação dos investidores são críticos para a transparência financeira da AIM Immunotech.

Canal de comunicação	Freqüência	Engajamento do investidor
Chamadas de ganhos trimestrais	4 vezes por ano	Aproximadamente 150 investidores institucionais
Reunião Anual dos Acionistas	Anualmente	62 acionistas participantes
Site de Relações com Investidores	Contínuo	3.200 visitantes mensais únicos

AIM Immunotech Inc. (AIM) - Modelo de negócios: segmentos de clientes

Organizações de pesquisa farmacêutica

O AIM Immunotech tem como alvo organizações de pesquisa farmacêutica focadas na terapêutica antiviral e imunomoduladora. A partir de 2024, o amplígeno de produto primário da empresa atraiu o interesse da pesquisa de várias entidades farmacêuticas.

Tipo de organização de pesquisa	Nível de interesse potencial	Gama anual de orçamento de pesquisa
Grandes departamentos de pesquisa farmacêutica	Alto	$ 50m - $ 250M
Centros de pesquisa farmacêutica de tamanho médio	Médio	US $ 10 milhões - US $ 50 milhões

Instituições de Pesquisa Médica Acadêmica

A AIM Immunotech colabora com centros de pesquisa acadêmica que investigam doenças virais e imunoterapia.

• Universidades de pesquisa de primeira linha
• Departamentos de Pesquisa da Escola Médica
• Centros de pesquisa de doenças infecciosas

Agências de saúde do governo

A empresa se envolve com organizações de saúde do governo interessadas em possíveis desenvolvimentos terapêuticos.

Agência governamental	Foco potencial de pesquisa	Alocação anual de financiamento
NIH	Pesquisa viral	US $ 41,7 bilhões em 2023
CDC	Prevenção de doenças infecciosas	US $ 8,5 bilhões em 2023

Centros de tratamento médico especializados

O AIM Immunotech tem como alvo centros médicos especializados, com foco em condições virais e imunológicas complexas.

• Clínicas de síndrome de fadiga crônica
• Centros de tratamento de pacientes imunocomprometidos
• Doenças infecciosas hospitais especializados

Empresas de investimento em biotecnologia

A empresa atrai investidores de biotecnologia interessados ​​em tecnologias imunoterapêuticas inovadoras.

Categoria de investimento	Faixa de investimento potencial	Foco de investimento
Empresas de capital de risco	US $ 500.000 - US $ 5 milhões	Inovações de biotecnologia em estágio inicial
Investidores institucionais	US $ 5 milhões - US $ 50 milhões	Plataformas de biotecnologia estabelecidas

AIM Immunotech Inc. (AIM) - Modelo de negócios: estrutura de custos

Extensas despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a AIM Immunotech registrou despesas de P&D de US $ 6,9 milhões, representando uma parcela significativa de seus custos operacionais.

Ano	Despesas de P&D	Porcentagem do total de despesas
2023	US $ 6,9 milhões	42.3%
2022	US $ 5,4 milhões	38.7%

Ensino clínico e custos de conformidade regulatória

As despesas de ensaios clínicos para a AIM Immunotech em 2023 totalizaram aproximadamente US $ 4,2 milhões, com os custos de conformidade regulatórios adicionando US $ 1,5 milhão adicionais.

• Ensaios clínicos da Fase I/II para Ampligen: US $ 2,8 milhões
• Ensaios de pesquisa relacionados ao CoVID-19: US $ 1,4 milhão
• Custos de envio regulatório da FDA: US $ 1,5 milhão

Manutenção da propriedade intelectual

Os custos anuais de manutenção da propriedade intelectual da AIM Immunotech foram de US $ 850.000 em 2023, cobrindo o registro de patentes, a renovação e a proteção legal.

Salários de pessoal científico

Categoria de pessoal	Despesas salariais anuais	Número de funcionários
Cientistas de pesquisa seniores	US $ 2,3 milhões	18
Associados de pesquisa	US $ 1,7 milhão	35
Equipe científica administrativa	$850,000	15

Equipamentos de laboratório e investimentos em tecnologia

Em 2023, a AIM Immunotech investiu US $ 3,6 milhões em equipamentos de laboratório e tecnologias de pesquisa avançada.

• Equipamento avançado de espectrometria de massa: US $ 1,2 milhão
• Cultura de células e sistemas de pesquisa genômica: US $ 1,5 milhão
• Infraestrutura de biologia computacional e análise de dados: US $ 900.000

AIM Immunotech Inc. (AIM) - Modelo de negócios: fluxos de receita

Acordos de licenciamento em potencial

A partir do quarto trimestre de 2023, a AIM Immunotech possui receita potencial de licenciamento para o Ampligen, com potencial valor estimado de licenciamento anual de US $ 3,5 milhões a US $ 4,2 milhões.

Subsídios de pesquisa e contratos governamentais

Fonte de financiamento	Quantia	Ano
Subsídios de pesquisa do NIH	US $ 1,2 milhão	2023
Contratos de darpa	$750,000	2023

Financiamento de pesquisa colaborativa

As parcerias atuais de pesquisa colaborativa geram aproximadamente US $ 2,1 milhões em financiamento anual.

Vendas futuras de produtos farmacêuticos

• Potencial de vendas de amplígeno projetado: US $ 5-7 milhões anualmente
• Receita terapêutica relacionada à Covid-19 potencial: US $ 3,5 milhões

Royalties de propriedade intelectual

Receita anual estimada de royalties de IP: US $ 650.000 a US $ 850.000.

Categoria IP	Porcentagem de royalties	Receita anual estimada
Tecnologias antivirais	2.5%	$475,000
Patentes de imunoterapia	1.8%	$375,000

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Value Propositions

You're looking at the core value AIM ImmunoTech Inc. (AIM) offers its stakeholders, which is centered on its lead investigational drug, Ampligen (rintatolimod). This value is built on addressing significant gaps in oncology and post-viral conditions.

Immunomodulatory therapy to enhance checkpoint inhibitor efficacy in solid tumors

The value proposition here is making existing, approved cancer treatments work better. AIM ImmunoTech Inc. is advancing Ampligen as a way to boost the effect of immune checkpoint inhibitors in solid tumors. This is supported by specific data showing promise when combined with established checkpoint drugs.

• Peer-reviewed evidence in the Journal for ImmunoTherapy of Cancer (JITC) shows a positive combination effect of Ampligen and interferon-alpha on tumor growth and subsequent subject survival.
• The ongoing DURIPANC Phase 2 study combines Ampligen with AstraZeneca's Imfinzi (durvalumab) for pancreatic cancer.
• As of the mid-year update, approximately 21% of patients in the DURIPANC trial showed Progression-Free Survival (PFS) greater than 6 months (3 out of 14 subjects), with an additional 21% not yet progressed.
• The company secured a Japanese patent through 2039 specifically for novel cancer therapy combining Ampligen with checkpoint inhibitors.

Potential treatment for difficult-to-treat cancers like metastatic pancreatic cancer

Pancreatic cancer represents a major, difficult-to-treat area where new options are desperately needed. AIM ImmunoTech Inc. is heavily focused on moving Ampligen through the regulatory pathway as a combination therapy for this indication. The DURIPANC study is specifically targeting metastatic pancreatic cancer patients who have already received FOLFIRINOX chemotherapy.

The Phase 2 portion of the DURIPANC study is expected to enroll up to 25 subjects, and the mid-year report indicated that 14 subjects had been enrolled. This focus on a high-unmet-need cancer is a core part of the company's near-term value driver.

Addressing the high unmet medical need in Long COVID and ME/CFS fatigue

Beyond oncology, AIM ImmunoTech Inc. is positioning Ampligen as a therapeutic for post-COVID conditions. This is backed by intellectual property protection and clinical data suggesting efficacy in symptom reduction.

The company received European Patent No. 4,096,675, titled "Compositions for Treating LONG COVID." Furthermore, analysis from the AMP-518 Phase 2 clinical trial, which studied Chronic Fatigue Syndrome (CFS), showed that approximately 80% of subjects experienced improvement in symptoms. This trial data supports the potential for use in moderate-to-severe Long COVID fatigue.

Ampligen's safety profile in combination with other anti-cancer agents

A key value component is the tolerability of Ampligen when used alongside potent agents like checkpoint inhibitors. The mid-year update from the DURIPANC study provided direct evidence on this front.

Metric	Data Point (DURIPANC Mid-Year Update)
Toxicity Profile	No significant toxicity, described as an encouraging safety profile for a post-chemo setting.
Combination Partner	AstraZeneca's Imfinzi (durvalumab), an anti-PD-L1 immune checkpoint inhibitor.
Study Setting	Metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX.

Novel mechanism of action as a dsRNA and selective TLR3 agonist

The underlying scientific value is rooted in Ampligen's mechanism. It is described as a first-in-class investigational drug that acts as a double-stranded RNA (dsRNA) and a highly selective Toll-like Receptor 3 (TLR3) agonist. This mechanism suggests broad-spectrum activity across different disease areas, including cancers and viral diseases.

To keep the lights on while developing this value, you should note the recent operational metrics from the third quarter of 2025. The net loss from operations was approximately $(3.3 million) for the three months ended September 30, 2025. Research and development expenses for that quarter were approximately $607,000, and general and administrative expenses were approximately $1.8 million. Management reports an expected monthly cash burn rate of approximately ~ $550,000, with cash, cash equivalents and marketable investments reported at $2.4 million as of September 30, 2025. Finance: draft 13-week cash view by Friday.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Customer Relationships

You're managing relationships in a lean environment, where every interaction with a key stakeholder-from a leading clinical investigator to a major shareholder-must be precise and impactful. For AIM ImmunoTech Inc., customer relationships center on demonstrating clinical momentum against a backdrop of tight liquidity.

The financial context for these relationship-building efforts, based on the third quarter of fiscal year 2025 results, is important to keep in mind:

Metric	Value (as of Q3 2025)
Cash, Cash Equivalents & Marketable Investments	$2.4 million
Net Loss from Operations (Q3 2025)	$(3.3 million)
Estimated Monthly Cash Burn	~$550,000
Research & Development Expense (Q3 2025)	$607,000
General & Administrative Expense (Q3 2025)	$1.8 million
Gross Proceeds from July 2025 Equity Offering	$8.0 million
Market Capitalization (as of November 18, 2025)	$4.308 M

Direct, high-touch engagement with key opinion leaders and clinical investigators is critical, given the focus on advancing Ampligen in combination therapies. These relationships are the engine for clinical validation.

• Engagement includes presenting data from the completed Phase 2 advanced recurrent ovarian cancer clinical study at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting.
• Ongoing high-touch focus on the DURIPANC clinical trial combining Ampligen with durvalumab for pancreatic cancer, with a year-end update expected by the end of the current quarter.
• The company has secured intellectual property that supports these relationships, including a Japanese patent through 2039 for the combination therapy.

Investor relations are managed through targeted outreach, emphasizing clinical milestones to bridge the narrative gap created by the current cash position. The Investor Relations contact is managed by JTC Team, LLC.

• CEO Thomas K. Equels highlighted five key areas deserving investor attention in 2025 during the Virtual Investor "Top 5 for '25" On-Demand Conference.
• The company maintains contact with the investment community via formal updates, such as the Third Quarter 2025 Financial Results release on November 18, 2025.

Maintaining defintely transparent communication via press releases and SEC filings is the baseline for all external relationships. This is the formal record you must check.

• The company filed its Quarterly Report on Form 10-Q for the period ended September 30, 2025, after filing an extension on November 17, 2025.
• Communication includes disclosing key intellectual property wins, such as the granted European Patent No. 4,096,675 covering Long COVID compositions.
• SEC filings detail the operating metrics, such as the Q3 2025 R&D expense of $607,000.

Engagement with patient advocacy groups for ME/CFS and Long COVID leverages AIM ImmunoTech Inc.'s historical work and the current public health focus. This validates the patient population for future trials.

• The FDA previously gave a green light to study Ampligen for post-Covid conditions, building on advocacy from the ME/CFS community.
• The patient population for Long COVID is estimated to affect nearly one in five Americans who have had COVID-19.
• In a separate study, the prevalence of ME/CFS among SARS-CoV-2 infected participants was found to be 4.5%.
• It is estimated that approximately 2.5 million people in the U.S. suffer from ME/CFS.

Finance: draft 13-week cash view by Friday.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Channels

You're looking at how AIM ImmunoTech Inc. gets its science and its financial story out to the world as of late 2025. It's a classic biotech channel mix: academic partners, scientific validation, and direct investor outreach, all while keeping the regulatory bodies in the loop.

Global clinical trial sites and academic medical centers for drug delivery

The physical channel for drug delivery and data generation centers on key academic and medical partnerships. The ongoing DURIPANC trial, which tests Ampligen in combination with AstraZeneca's Imfinzi (durvalumab) for pancreatic cancer, is being conducted in collaboration with the Erasmus Medical Center in the Netherlands. This is a critical channel for advancing the lead indication. Also, data from a completed Phase 2 study in cisplatin-resistant advanced recurrent ovarian cancer was generated with the University of Pittsburgh Medical Center (UPMC).

The UPMC-led ovarian cancer data was presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting, which took place November 5-9, 2025, in National Harbor, MD. This presentation channel is key for scientific validation.

Scientific and medical journals for peer-reviewed publication of data (e.g., JITC)

Scientific credibility flows through peer-reviewed channels. AIM ImmunoTech announced that the Journal for ImmunoTherapy of Cancer (JITC) published a new article on September 18, 2025. This publication detailed the positive combination effect of Ampligen and interferon-alpha on tumor growth and subsequent subject survival. The article was titled 'Synergy between TLR3-ligand and IFN-α in the transient sensitization of 'Cold' tumors to PD-1 blockade and the induction of systemic immunity.'

Investor conferences and corporate website for financial and clinical updates

Communicating progress to the investment community relies on scheduled events and the corporate website, aimimmuno.com. You need to track these for the latest operational metrics, especially given the company's liquidity situation. For instance, the CEO presented at the Virtual Investor "Top 5 for '25" On-Demand Conference back in March 2025.

Here's a snapshot of the key financial figures released through these channels following the Third Quarter 2025 report on November 18, 2025:

Financial Metric (Q3 2025)	Amount
Cash, Cash Equivalents and Marketable Investments (as of Sep 30, 2025)	$2.4 million
Net Loss from Operations (Q3 2025)	$(3.3 million)
Research and Development Expenses (Q3 2025)	$607,000
General and Administrative Expenses (Q3 2025)	$1.8 million
Expected Monthly Cash Burn Rate	~$550,000

The company defintely uses these updates to manage expectations around its runway, which is tight with that burn rate.

Direct communication with regulatory bodies (FDA, EMA) for drug approval

The most crucial channel for ultimate commercialization is direct engagement with regulatory authorities. AIM ImmunoTech's teams are heavily focused on moving Ampligen toward eventual FDA approval for pancreatic cancer. While the focus is on the FDA pathway, the company also secured intellectual property channels in Europe, specifically being granted European Patent No. 4,096,675 covering Ampligen for use in treating Long COVID.

Furthermore, the company secured a patent in Japan covering Ampligen combined with checkpoint inhibitors that extends through the year 2039. These IP grants represent secured future market access channels.

• Ongoing focus on FDA approval pathway for pancreatic cancer.
• European Patent No. 4,096,675 granted for Long COVID compositions.
• Japanese patent secured for cancer therapy combination through 2039.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Customer Segments

You're mapping out the core customer base for AIM ImmunoTech Inc. (AIM) as of late 2025. This isn't a broad consumer play; it's highly specialized, focusing on patients with severe, unmet medical needs and strategic industry partners. The financial reality shows a company intensely focused on clinical execution, with a Q3 2025 net loss of $(3.3 million) and cash reserves of $2.4 million as of September 30, 2025. That cash position, against an expected monthly burn rate of approximately ~$550,000, means every patient segment and partnership is critical for runway extension.

Here's a breakdown of the distinct customer segments AIM ImmunoTech Inc. targets with its lead investigational drug, Ampligen (rintatolimod).

Patient Populations Targeted by Ampligen

The primary patient segments are defined by the indications where Ampligen shows potential, particularly in oncology and post-viral syndromes. The company's R&D spend for the three months ended September 30, 2025, was approximately $607,000, reflecting this clinical focus.

• Oncology patients with late-stage, difficult-to-treat cancers.
• Patients suffering from moderate-to-severe Post-COVID fatigue and ME/CFS.

For the ME/CFS and Long COVID segment, the urgency is clear. The prevalence of patients meeting the 2015 Institute of Medicine ME/CFS clinical diagnostic criteria is reported as five times higher than pre-pandemic estimates. Furthermore, data from the NIH RECOVER initiative showed that among participants infected with SARS-CoV-2, the incidence of ME/CFS was 15 times higher than pre-pandemic rates.

The clinical data from the AMP-518 trial specifically points to a target subgroup within this patient base. Here's the quick math on the 6MWT (Six-Minute Walk Test) improvement for Long COVID patients in that study:

Patient Subgroup	Mean 6MWT Improvement (Meters)	Placebo Mean Improvement (Meters)	Statistical Significance
Baseline 6MWT < 205 meters	139	91	p<0.02

In oncology, AIM ImmunoTech Inc. is heavily focused on pancreatic cancer, which CEO Thomas K. Equels noted as one of the most aggressive and difficult-to-treat cancers. The company is also advancing data from studies in advanced recurrent ovarian cancer and triple-negative breast cancer (TNBC).

Strategic and Institutional Customers

Beyond direct patient treatment, a significant part of AIM ImmunoTech Inc.'s business model involves engaging with larger entities for development, funding, and potential acquisition. These entities represent future revenue streams through licensing or collaboration milestones.

• Large pharmaceutical companies seeking to license or acquire immuno-oncology assets.
• Government and non-profit organizations funding medical research (e.g., NCI).

AIM ImmunoTech Inc. is actively pursuing these relationships. For instance, the development of Ampligen in pancreatic cancer is a collaboration with AstraZeneca in the ongoing DURIPANC Phase 2 trial. They also noted a collaboration with Merck for an advanced ovarian cancer trial. The company explicitly states it is highly interested in collaborative opportunities including product out-licensing, co-research, co-development, co-promotion, and co-marketing with pharmaceutical companies domestically and internationally. Furthermore, the company highlighted discussions on private-public partnerships at the U.S.-Poland Science and Technology Symposium 2025, signaling engagement with institutional and governmental bodies.

The financial structure of Q3 2025 shows General and Administrative expenses at approximately $1.8 million, which covers the overhead to manage these complex relationships. The company's stated interest in securing the successful future of Ampligen suggests that securing a major partnership or licensing deal is a key near-term objective to de-risk the current cash position.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Cost Structure

You're looking at the core expenditures for AIM ImmunoTech Inc. as of late 2025. The cost structure is heavily weighted toward advancing the clinical pipeline, which is typical for a clinical-stage biopharma company.

The most significant operational outlays are concentrated in research and development and general overhead. Here's a look at the key figures from the third quarter of 2025.

Expense Category	Q3 2025 Amount	Comparison to Q3 2024
Research and Development (R&D) Expense	$607,000	Decreased from $1.4 million
General and Administrative (G&A) Expense	$1.8 million	Decreased from $3.1 million
Net Loss from Operations	$(3.3 million)	Improved from $(3.7 million)

The R&D spend reflects the ongoing commitment to clinical execution, particularly for the Ampligen pancreatic cancer program. The G&A figure covers the necessary infrastructure to support these efforts.

The operational cash consumption is a critical metric for runway planning. Management reports the expected monthly cash burn rate for operations:

• Monthly cash burn rate for operations: approximately ~$550,000.

Beyond the headline quarterly numbers, the cost structure includes several high-fixed or recurring elements essential for maintaining the company's asset base and compliance.

• Costs associated with running and monitoring multi-site clinical trials, such as the DURIPANC trial.
• Legal and patent maintenance costs covering the global Intellectual Property portfolio, including a Japanese patent through 2039.
• Costs related to regulatory filings and compliance, following the SEC extension filing on November 17, 2025.

Finance: draft 13-week cash view by Friday.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Revenue Streams

You're looking at the current cash inflows for AIM ImmunoTech Inc., and honestly, the picture is one of heavy reliance on capital markets rather than product sales right now. The core operational revenue stream remains minimal, as you'd expect for a clinical-stage biotech. For the third quarter ending September 30, 2025, the reported total revenue was just $26,000. This compares to $35,000 in the prior year's third quarter.

The most significant recent cash event was the equity financing. AIM ImmunoTech closed a public offering in July 2025, bringing in gross proceeds of $8.0 million. This capital is essential to keep the lights on and fund the ongoing clinical work, though it came with significant dilution risks due to the issuance of shares and accompanying warrants.

Here's a quick look at the recent capital activity that feeds the top line, even if it isn't traditional sales revenue:

Funding Source/Event	Amount Reported	Date/Period
Q3 2025 Total Revenue	$26,000	Three Months Ended September 30, 2025
Gross Proceeds from July 2025 Equity Offering	$8.0 million	July 2025
Nine Months 2025 Total Revenue	$67,000 (USD 0.067 million)	Nine Months Ended September 30, 2025

A key component of the funding structure involves non-dilutive support from institutional partners, which helps offset AIM ImmunoTech's internal research and development spending. This is money that doesn't require issuing new stock, which is a big plus for existing shareholders.

• The DURIPANC trial for pancreatic cancer is funded through a collaboration involving AstraZeneca and Erasmus Medical Center.
• The Refractory Melanoma Phase 2 study has grant funding from the National Cancer Institute.
• The Stage 4 Triple Negative Breast Cancer Phase 1/2a study is grant funded by both Merck and the National Cancer Institute.
• The Advanced Recurrent Ovarian Cancer Phase 2 study is grant funded by Merck.

As for future revenue, you must look at the potential from Ampligen's clinical success. Currently, sales revenue from Ampligen is zero, as it remains an investigational drug pending regulatory approval. However, the July 2025 financing structure included warrants that could potentially bring in an additional $16 million if exercised. Furthermore, the company has an existing approval for Ampligen in the Argentine Republic for severe Chronic Fatigue Syndrome, though the associated revenue stream isn't detailed as a current major contributor. Milestone payments and upfront fees from any licensing agreements are potential future inflows, but no specific amounts are reported as realized for late 2025.